СПОСОБ ИНГИБИРОВАНИЯ АКТИВНОСТИ ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА - HJV IN VIVO В ЭКСПЕРИМЕНТЕ

Изобретение относится к медицине и может быть использовано для ингибирования активности человеческого вируса иммунодефицита HJV in vivo в эксперименте путем введения противомалярийного средства - примахина. Антималярийное средство вводят в дозе, достаточной для предотвращения или по меньшей мере ингибирования инфекции Т лимфоцитов вирусом HJV in vivo или для предотвращения или по меньшей мере ингибирования репликации HJV in vivo 3 табл.

СПОСОБ ЛЕЧЕНИЯ ПАЦИЕНТОВ С ПЕРВИЧНЫМ ПОРАЖЕНИЕМ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ

Способ относится к медицине, в частности к лечению первичного поражения центральной нервной системы с применением гомеопатических средств. Сущьность изобретения: при лечении больных с первичным поражением центральной нервной системы необходимо оценить уровень трех типов рефлексов: рук, коленей и подошв. Если уровень всех трех видов рефлексов у пациента низкий, то ему следует назначать препараты Бария, или Хинин валерьян, или Амбра гризеа. При умеренном уровне всех типов рефлексов пациентам следует назначать Гиперикум, а при патологически высоком - Латирус сативум.

АНТИМАЛЯРИЙНЫЕ СИНЕРГЕТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ БЕНФЛУМЕТОЛ

Настоящее изобретение относится к синергетическим антималярийным композициям, которые содержат антималярийный агент бенфлуметол, а также антималярийный агент из хининовой группы такой, как хинин. Эти композиции можно включить в твердые дозированные формы, такие, как таблетки, и использовать для лечения стойкой к лекарственным препаратам малярии.

ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ С РЕГУЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ ДЛЯ ПЕРОРАЛЬНОГО ВВЕДЕНИЯ, СОДЕРЖАЩАЯ В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА НИФЕДИПИН, СПОСОБ ЕЕ ПОЛУЧЕНИЯ

... 1. Фармацевтическая композиция с регулируемым высвобождением для перорального введения, содержащая в качестве активного вещества нифедипин, отличающаяся тем, что включает аморфный продукт соосаждения нифедипина и поливинилпирролидона; гидрофильное производное целлюлозы в количестве, варьирурующем по массе от 0,1 до 6 раз относительно количества нифедипина; карбоксиполиметилен и лактозу в количестве, варьирующем по массе от 0,1 до 5 раз относительно количества нифедипина и защитную или задерживающую растворение поверхностную оболочку. 2. Композиция по п. 1, отличающаяся тем, что соотношение массовых количеств нифедипина и поливинилпирролидона в указанном продукте соосаждения от 1 : 1 до 1 : 5. 3. Композиция по п. 1, отличающаяся тем, что высвобождение нифедипина может быть изменено от 8 до 24 ч. 4. Композиция по п. 1, отличающаяся тем, что позволяет использовать схему дозирования, включающую одноразовое или двухразовое ежедневное введение. 5. Композиция по п. 1, отличающаяся тем, что содержание ...

Neue therapeutische Konzepte für die Behandlung von Fibromyalgien

Die Erfindung betrifft neue Konzepte für die prophyfaktische und/oder therapeutische (kurative) Behandlung von in der Human- oder Veterinärmedizin auftretenden, durch eine Fehlsteuerung der Schmerzreizleitung hervorgerufenen bzw. durch die Hemmung der Schmerzreizleitung behandelbaren Erkrankungen, insbesondere Fibromyalgien.

TRAEGERMASSEN FUER DIE KONTROLLIERTE FREISETZUNG PHARMAZEUTISCHER WIRKSTOFFE.

Nervenschutzende für Auge von Säugern unter Anwendung von Kaliumkanalblockern

VERFAHREN ZUR HERSTELLUNG EINER CHINIDIN-ARZNEIFORM MIT GLEICHMAESSIG VERZOEGERTER ARZNEISTOFFFREIGABE

Extrakt aus grünen Kaffeebohnen, pharmazeutische Zubereitung enthaltend diesen Extrakt, Verwendung zur Behandlung von Depressionen und Akloholismus sowie Herstellungsverfahren

Hemorrhoidal compositions containing topical anesthetics

A composition adapted for the local treatment of hemorrhoids comprises, as co-active ingredients, the aluminium salt of alpha-hydroxypropionic acid (aluminium lactate), a topical anaesthetic and, as a "modifier" to promote interaction between the said ingredients, a cellulose ether, a sodium salt of an anionic surface-active agent or a surface-active fatty acid ester of a polyhydroxy compound. Topical anaesthetics specified are ethyl para-aminobenzoate, 2, diethylaminoethyl ester of para-aminobenzoic acid, 2-butoxy-N-(2-diethylaminoethyl)-cinchoninamide hydrochloride, 2 - (isobutylamino) - ethyl para-aminobenzoate hydrochloride and 2 - dimethylaminoethyl ester of para-butylaminobenzoic acid. Specified "modifiers" are sodium carboxymethylcellulose, methyl cellulose, dioctyl sodium sulphosuccinate, sodium lauryl sulphate, sorbitan mono-oleate and sorbitan mono-oleate polyethylene ether. The compositions are used in the form of ointments or suppositories, generally made up in a water soluble ...

Dihydroquinidine salts

The invention comprises dihydroquinidine galacturonate and its preparation by reacting in an inert solvent either (a) dihydroquinidine and galacturonic acid or (b) an acid addition salt of dihydroquinidine and an alkali metal salt of galacturonic acid.ALSO:The invention comprises dihydroquinidine polygalacturonate and its preparation by reacting in an inert solvent either (a) dihydroquinidine and polygalacturonic acid or (b) an acid addition salt of dihydroquinidine and an alkali metal salt of polygalacturonic acid.ALSO:Pharmaceutical compositions used to combat cardiac arrhythmia comprise dihydroquinidine galacturonate or dihydroquinidine polygalacturonate in combination with a pharmaceutical carrier, for example in forms suitable for oral, parenteral or rectal administration, such as tablets, capsules, ampoules, solutions or suppositories.

The treatment of degenerative diseases

Quinine polygalacturonate

Novel quinine polygalacturonate is prepared by either reacting quinine with polygalacturonic acid until the pH of the mixture is 6-7.5 or reacting an aqueous solution of a quinine salt with an aqueous solution of an alkali or alkaline earth metal salt of polygalacturonic acid until the pH of the solution is 6-7.5. Pharmaceutical compositions comprise quinine polygalacturonate in conjunction with a diluent and may be administered orally or parenterally. They are effective in treatment of malaria.

Use of cyp2d6 inhibitors in combination therapies

BIS-AZA-BICYCLIC ANXIOLYTIC AGENTS

Inhibition of the replication of HIV and related viruses using thiourea derivative compounds or salts thereof.

Method of aids, inhibition of the replication of hiv by contacting hiv with a compound of the formula-(see file) ...

Bis-aza-bicyclic anxiolytic agents.

The invention is directed to the provision of ...

Inhibition of the replicateion of HIV and related viruses using thiourea derivative compounds or salts thereof.

Method for inhibiting the replication of hiv by contacting hiv with a compound of the formula: ...

Quinoline derivatives and their use as mycobacterial inhibitors.

BIS-AZA-BICYCLIC ANXIOLYTIC AGENTS

Use of CYP2D6 inhibitors in combination therapies.

This invention relates to the use of a CYP2D6 inhibitor in combination with a drug having CYP2D6 catalyzed metabolism, wherein drug and the CYP2D6 inhibitor are not the same compound; and pharmaceutical compositons for said use.

COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES

Inhihition of the replication of hiv and related viruses using thiourea derivative compounds or salts thereof

Use of cyp2d6 inhibitors in combination therapies

Use of CYP2D6 inhibitors in combination therapies.

Pharmaceutical composition intended to fight the paludism and its method of preparation

Antimalarial compositions containing cis-fused cyclopenteno-1,2,4-trioxane derivatives

“Derived from amino-acids”.

New liquid composition containing quinine formate.

Pharmaceutical compositions containing of quinine.

Synergistic anti-paludic compositions containing benflumetol

Bis-aza-bicyclic anxiolytic agents

Preparation of combination for the treatment of the malaria.

COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES

Inhihition of the replication of hiv and related viruses using thiourea derivative compounds or salts thereof

COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES

PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS

ADMINISTRATION OF OPIOIDEN BY INHALATION

ADMINISTRATION OF ALPRAZOLAM, ESTAZOLAM, MIDAZOLAM OR TRIAZOLAM BY INHALATION

ADMINISTRATION OF ANTIMIGRÄNEMITTELN BY INHALATION

N-ALKYLATING QUARTÄRE NITROGENOUS ONE HETERO CYCLES, PROCEDURE FOR THEIR PRODUCTION AND THEIR USE IN DRUGS

BEVERAGE, CONTAINING FRUCTOSE, VITAMIN C, CHININ AND/OR THEIR SUBSTITUTES.

PHARMACEUTICAL COMPOSITIONS.

PROCEDURE FOR INHIBIERUNG THE EFFECT OF THE HUMAN IMMUNE WEAKNESS VIRUS (HIV) IN VIVO.

PHARMACEUTICAL COMPOSITIONS OF CINCHONIN DIHYDROCHLORID

USE OF (+) MEFLOQUINE FOR THE TREATMENT OF MALARIA

Method and composition for modulating amyloidosis

Rho/ROCK/P13/Akt kinase inhibitors for the treatment of diseases associated with protozoan parasites

8-ARYLALKYL-3-PHENYL-3-NORTROPANOLS

USE OF INTERFERON AND A SUBSTRATE WITH AN ANTIMALARIAL ACTIVITY FOR THE TREATMENT OF MALARIA INFECTIONS

The treatment of inflammatory disorders

Quinuclidine-substituted aryl compounds for treatment of disease

PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS

Quinine compounds, and optical isomers, preparation method and medical use thereof

Disclosed in the present invention are quinine compounds, and pharmaceutically acceptable salts, solvates, precursors and optical isomers thereof. Also disclosed in the present invention are that the above compounds have a selective blocking effect on the receptor subtypes M ...

Use of enhancers, possibly associated to riboflavin, as well as corresponding ophthalmic compositions for corneal cross-linking in the treatment of the keratoconus or of other corneal ectasic disorders

Described herein is the use of enhancers with possibly riboflavin, as well as the corresponding compositions for the treatment of keratoconus or other ectasic corneal disorders by means of the method of corneal cross-linking.

METHOD OF INHIBITING THE ACTIVITY OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN VIVO

ANTIMALARIAL COMPOSITIONS

DRUG COMBINATIONS COMPRISING (E)-7-¬4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-¬METHYL(METHYLSULFONYL)AMINO│PYRIMIDIN-5-YL│(3R,5S)-3,5-DIHYDROXYHEPT-6-ENOIC ACID AND AN INHIBITOR, INDUCER OR SUBSTRATE OF P450 ISOENZYME 3A4

The invention concerns safe non-interacting drug combinations of a 3-hydroxy - 3- methylglutaryl coenzyme A(HMG-CoA) reductase inhibitor, which is (E)-7-[4-(4-fluorophenyl)-6- isopropyl -2- [methyl (methylsulfonyl) amino] pyrimidin-5-yl](3R,5S)-3,5--dihydroxyhept -6-enoic acid or a pharmaceutically acceptable salt thereof (the Agent) and a drug which is either an inducer, inhibitor or a substrate of cytochrome P450, in particular cytochrome P450 isoenzyme 3A4. Particular combinations are useful in treating hyperlipidaemia in humans who are receiving immunosuppressive chemotherapy. A preferred combination is the Agent and a fibrate drug, the use of such a combination in treating hyperlipidaemia in mammals, and medicaments containing such a combination for use in such treatments.

DELIVERY OF ANTIHISTAMINES THROUGH AN INHALATION ROUTE

The present invention relates to the delivery of antihistamines through an inhalation route. Specifically, it relates to aerosols containing antihistamines that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of an antihistamine. In a method aspect of the present invention, an antihistamine is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of an antihistamine, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. In a kit aspect of the present invention, a kit for delivering an antihistamine through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of an antihistamine; and, b) a device that forms an antihistamine ...

DELIVERY OF COMPOUNDS FOR THE TREATMENT OF MIGRAINE THROUGH AN INHALATION ROUTE

The present invention relates to the delivery of a migraine headache drug through an inhalation route. Specifically, it relates to aerosols containing a migraine headache drug that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of a migraine headache drug. In a method aspect of the present invention, a migraine headache drug is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of a migraine headache drug, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol compressing particles, which is inhaled by the mammal. In a kit aspect of the present invention, a kit for delivering a migraine headache drug through an inhalation route to a mammal is provided which comprises: a) a composition compressing at least 5 percent by weight of a migraine ...

EXTENDED ACTION CONTROLLED RELEASE COMPOSITIONS

Extended action controlled release compositions are formed by incorporating into a controlled release matrix for a medication a mixture of the salt form of the medication and the free base form of the medication in a proportion of 75%-25% by weight of the salt form to 25%-75% by weight of the free base form, the weight amounts being calculated with respect to the active base.

AGENTS FOR INHALATION THERAPY OF BRONCHIAL DISEASES

2,5,6-SUBSTITUTED-N -ALKYLPYRIMIDINES

The synthesis and application of N(1)-n-alkyl-pyrimidinium-salts are described. These surfactants have a very small critical micelle concentration (CMC) in the order of 10-5 10-7 Mol/Liter. These N(1)-n-alkyl-pyrimidinium components have pharmacological activities and can act as antimetabolites.

PHARMACEUTICAL PREPARATIONS

A pharmaceutical preparation is disclosed which is made up of a micelle or a vesicle each consisting of a cationic tenside with a monovalent ion and a hydrophobic cyclic or linear peptide, dispersed in a solvent whose pH value lies between pH 7 - pH 8, the critical micellization concentration (cmc) lying in the range of 1.0 . 10-7 to 7.0 . 10-5 mol/litre. The preparations disclosed have in particular the advantage that by the increasing of the hydrophobicity of the alkyl or aryl chain or the radical at the N+ tenside both the membrane permeability is increased and furthermore the pharmaceutical active substance, in particular linear and cyclic tyrocidines (A - E), can be transferred actively into the cytosol. They thus act on the transcription level. In addition, linear and cyclic tyrocidines in particular have antiviral effects.

N-ALKYLATED QUATERNARY NITROGEN-CONTAINING HETEROCYCLES

The synthesis of 4-, 4-(1,1)- and 3,5- substituted N-alkyl-pyri-dinium salts as well as of 2-carboxamide substituted N(1,4)diazinium componunds are described. The N-surfactants obtained have a small critical micelle concentration (CMC) of 10-5 - 10-7 Mol/ Liter. These surfactants produce micells of different size and form depending on the nature of the anions. 4-(1,1)-substituted and 3,5-substituted N-alkyl-pyridinium components are capable of forming vesicles in equeous solutions of different forms and sizes. The N-surfactants synthesized can be used as pharmaceuticals.

DELIVERY OF OPIOIDS THROUGH AN INHALATION ROUTE

The present invention relates to the delivery of opioids through an inhalation route. Specifically, it relates to aerosols containing opioids that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of an opioid. In a method aspect of the present invention, an opioid is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of an opioid, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. In a kit aspect of the present invention, a kit for delivering an opioid through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of an opioid; and, b) a device that forms an opioid aerosol from the composition, for inhalation by the mammal ...

COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS

The present application relates to compositions which modulate the activity of gated ion channels. This provide an effect in the treatment of pain, inflammatory disorders and neurological disorders. Preferred compounds include quinine or quinidine derivatives with the hydroxyl at the nine position being esterified with an aliphatic carboxylic acid, optionally bearing an additional cycloalkyl ring on the chain. The gated ion channels modulated include homomultimeric and heteromultimeric gates.

CHEMOTHERAPEUTIC MICROEMULSION COMPOSITIONS OF PACLITAXEL WITH IMPROVED ORAL BIOAVAILABILITY

Pharmaceutical compositions suitable for oral administration comprising paclitaxel, a solvent, a surfactant, a substituted cellulosic polymer, and optionally but preferably a P-glycoprotein inhibitor. The composition may further comprise a diglyceride or mixture of diglyceride and monoglyceride. The composition generates a supersaturated paclitaxel microemulsion upon contact with water resulting in improved oral bioavailability of paclitaxel.

PALLADIUM-SUBSTITUTED BACTERIOCHLOROPHYLL DERIVATIVES AND USE THEREOF

... ▓▓▓Palladium-substituted Bacteriochlorophyll derivatives of formula (I), wherein ▓A represents OH, OR1, -O-(CH2)n-Y, -S-(CH2)n-Y, -NH-(CH2)n-Y, -O-(CH2)2-NH2, -▓O-(CH2)2-OH, -NH-(CH2)n- +N o, X-, -NH-(CH2)2-NH=BOC or -N-(CH2-CH=CH2)2; ▓wherein R1 represents Na+, K+, (Ca2+)0,5, (Mg2+)0,5, Li+, NH4+, +NH3-▓C(CH2OH)3, +NH3-CH2-(CHOH)4-CH2OH, +NH2(CH3)-CH2-(CHOH)4-CH2OH or ▓+N(Cn'H2n'+1)4; R2 represents H, OH or COOR4, wherein R4 is C1-C12 alkyl or C3-▓C12 cycloalkyl; R3 represents H, OH or C1-C12 alkyl or alkoxy; n is 1, 2, 3, ▓4, 5 or 6, Y is -NR'1R'2 or -+NR'1R'2R'3, X- wherein R'1, R'2 and R'3 ▓independently from each other represent -CH3 or -C2H5; X is F, Cl, Br or l, n' ▓is 1, 2, 3 or 4 and their oxidized forms, are useful in the field of ▓photodynamic therapy (PDT).▓ ...

METHODS FOR THE TREATMENT OF CANCER WITH IRINOTECAN BASED ON CYP3A5

The present invention relates to the use of irinotecan or a derivative thereof for the preparation of a pharmaceutical composition for treating cancer, especially, colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer in a patient having a genotype with a variant allele which comprises a polynucleotide in accordance with the present invention. Preferably, a nucleotide deletion, addition and/or substitution comprised by said polynucleotide results in an altered expression of variant allele compared to the corresponding wild type allele or an altered activity of the polypeptide encoded by the variant allele compared to the polypeptide encoded by the corresponding wild type allele. Finally, the present invention relates to a method for selecting a suitable therapy for a subject suffering from cancer, especially, colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic ...

MEDICAMENT A ACTION VASODILATATRICE ET SPASMOLYTIQUE

DELIVERY OF OPIOIDS THROUGH AN INHALATION ROUTE

The present invention relates to the delivery of opioids through an inhalation route. Specifically, it relates to aerosols containing opioids that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of an opioid. In a method aspect of the present invention, an opioid is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of an opioid, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. In a kit aspect of the present invention, a kit for delivering an opioid through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of an opioid; and, b) a device that forms an opioid aerosol from the composition, for inhalation by the mammal ...

PHARMACEUTICAL COMPOSITIONS COMPRISING A DEXTROMETHORPHAN COMPOUND AND QUINIDINE FOR THE TREATMENT OF AGITATION IN DEMENTIA

The present disclosure is related to methods of treating agitation and/or aggression and/or associated symptoms in subjects with dementia, including, dementia associated with Alzheimer's disease. The method includes administering to a subject in need thereof a dextromethorphan compound, or a pharmaceutically acceptable salt thereof, in combination with quinidine, or a pharmaceutically acceptable salt thereof. The disclosure in certain aspects is also related to compositions that are used for treating agitation and/or aggression and/or associated symptoms in subjects suffering from Alzheimer's disease.

USE OF OXIDASE INHIBITOR WITH DEXTROMETHORPHAN TO TREAT INTRACTABLE COUGHING AND DERMATITIS

This invention discloses a method for increasing the effectiveness of dextromethorphan (DM) in treating either severe coughing or dermatitis which do not respond to other drug treatments. This method involves the administration, to a patient who is an extensive metabolizer of dextromethorphan and who is suffering from severe coughing or dermatitis, of dextromethorphan along with a second agent that inhibits the enzymatic activity of debrisoquin hydroxylase (also called sparteine monooxygenase, cytochrome P450 DB, and cytochrome P450-2D6). Quinidine is an especially potent inhibitor of enzymatic DM oxidation, but it is not well tolerated by everyone. other antioxidants which are less potent and better tolerated by some patients include quinine, yohimbine, fluoxetine, haloperidol, ajmaline, lobeline, and pipamperone. Since people have major variations in their oxidative enzyme activities, screening tests should be undertaken under the supervision of a physician to select a preferred antioxidant ...

CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES

Methods of modulating hormone concentrations in a subject comprising the administration of a composition comprising a chemosensory receptor ligand, wherein the composition is adapted to deliver the ligand to one or more regions of the intestine of said subject. Methods are directed to the modulation of circulating concentrations of one or more ofGLP-l (total), GLP-I (active), GLP-2, oxyntomodulin, PYY (total), PYY 3-36, CCK, GIP, insulin, C-peptide, glycentin, uroguanylin amylin, and ghrelin (total), ghrelin (active) and glucagon.

USE OF INTERFERON AND A SUBSTANCE WITH AN ANTIMALARIAL ACTIVITY FOR THE TREATMENT OF MALARIA INFECTIONS

Use of interferon and a substanee with an antimalarial activity for the treatment of malaria infections Clinical (erythrocytic) malaria may be treated by administering effective amounts of an interferon, e.g. IFN-.gamma., and at least one antimalarially active substance which is preferably selected from 9-aminoacridines, 4aminoquinolines, 8-aminoquinolines, biguanides, diaminopyrimidines, quinine salts, sulphonamides, sulfanilamides, antibiotics and/or sulphones e.g. chloroquine ¢(7-chloro-4-(4-diethylamino-1-methylbutylamino)-quinoline!.

TRICYCLIC COMPOUNDS

NEW TRICYCLIC COMPOUNDS 5-HT receptor antagonist compounds of Formula I in which: the dashed line denotes an optional bond; X and Y are independently selected from hydrogen, halogen, hydroxy, lower alkoxy, benzyloxy, lower alkyl, nitro, amino, aminocarbonyl, (lower alkyl)amino, di(lower alkyl)amino, and (lower alkanoyl)amino; Z is -O-, -S- or -N(R2)-; R1 and R2 are independently selected from hydrogen and lower alkyl or are together -(CH2)n- wherein n is an integer from 2 to 4; and FF27170.HVM 27170-FF R3 is selected from (a) (b) (c) (d) in which: p is 0 or 1; q is 1, 2 or 3; and R4 is C1-7 alkyl; their pharmaceutically acceptable salts, individual isomers or mixtures of isomers, processes for their preparation, compositions containing them, and their methods of use. FF27170.HVM 27170-FF ...

COMPOUNDS AND METHODS FOR INHIBITION OF HIV AND RELATED VIRUSES

Treatment of Aids, inhibition of the replication of HIV and related viruses, and formulations using thiourea derivative compounds or salts thereof are disclosed. Also disclosed are novel thiourea compounds.

USE OF ANTIARRHYTHMIC AGENTS TO LOWER CHOLESTEROL

... 2089164 9222299 PCTABS00018 A method is provided to lower serum cholesterol, total triglycerides and/or apoprotein B in a human by administering an effective amount of one or more Type IA antiarrhythmic agents to said human.

FORMULATION FOR IRON CHELATION, A PROCESS FOR PREPARING THE FORMULATION AND A METHOD OF TREATING THALASSEMIA

A pharmaceutical formulation useful for treating patients suffering fro m thalassemia, which comprises powder of Anemonin Pretensis in an amount in the range of 0.02 to 0.12 wt % of the formulation, quinine sulphate in an amount in the range of 0.0005 to 0.003 wt % of the formulation, distilled or demineralised water in an amount in the range of 0 to 40 wt % of the formulation, and ethanol in an amount in the range of 99.88 to 60 wt % of the formulation; and a process for preparing the formulation by mixing the above ingredients.

Verfahren zur Darstellung einer Chinin-Eiweissverbindung.

Verfahren zur Herstellung von therapeutisch verwendbarem Dihydrochinidin-Galakturonat und Dihydrochinidin-Polygalakturonaten

Verfahren zur Herstellung von Chininpolygalacturonat

Anticancer compsns. - consists of a cytotoxic agent with a agent to prevent multi:drug resistance, e.g. in liposome(s)

Compsns. consist of: (a) a cpd. (I) having a cytotoxic effect, (b) a non-cytotoxic material (II) having an inhibiting effect on anti-cancer multi-drug resistance, and (c) a vehicle for both (I) and (II). Pref. the vehicle (III) may be, e.g., a microparticle, microcapsule, nanoparticle or nanocapsule. The cytotoxic material (I) may be a vinca alkaloid, an anthracyclin, an epipodophyllotoxin, or an antitumoral antibiotic, e.g., vincristine, vinblastine, doxorubicin, tetrahydropyranyl adriamycin, daunorubicin, m-amsa, bisanthrene, and ethidium bromide. The non-cytotoxic material (II) may be e.g. amiodorone, quinine, quinidine, cinchonine, verapamil, cyclosporin A, biperidene, lidocaine, chlorpromazine, pentazocine, promethazine, amitriptyline, propanolol, thioridazine, reserpine, etc.. The components (I) and (II) may both be fixed in the same part of the vehicle (III), or one may be fixed in the vacuity of the vehicle and the other fixed in the membrane of the vehicle. These are pref. formulated ...

Use of cinchonine, di:hydro:cinchonine or hydro:quinidine

Use of cinchonine (I); dihydrocinchonine (II) or hydroquinidine (III) to inhibit multidrug resistance (MDR) in the treatment of cancerous tumours with cytotoxic agents (A) is new. The same cpds. also reinforce the activity of (A) against MDR cells. (I)-(III) can be used as pure stereoisomers/enantiomers or as their mixts. They are formulated with a particulate vehicle, i.e. a micro-or nano-particle or a micro- or nano-capsule, esp. a liposome.

Use of cinchonine, di:hydro:cinchonine or hydro:quinidine

Use of cinchonine (I); dihydrocinchonine (II) or hydroquinidine (III) to inhibit multidrug resistance (MDR) in the treatment of cancerous tumours with cytotoxic agents (A) is new. The same cpds. also reinforce the activity of (A) against MDR cells. (I)-(III) can be used as pure stereoisomers/enantiomers or as their mixts. They are formulated with a particulate vehicle, i.e. a micro-or nano-particle or a micro- or nano-capsule, esp. a liposome.

APPLICATION FOTOUSILIVAYuShchIKh AGENTS IN ASSOCIATION WITH RIBOFLAVIN, AND ALSO CORRESPONDING OPHTHALMOLOGIC COMPOSITIONS FOR CROSS-CROSS-LINKING CORNEA AT TREATMENT OF KERATOCONUS OR OTHER EKTAZIINYKh DISORDERS CORNEA

THERAPY OF NEURODEGENERATIVE DISEASES

COMBINATION ZALTOPROFENA AND MYORELAXANT

СПОСОБ ПРОФИЛАКТИКИ И/ИЛИ ТЕРАПЕВТИЧЕСКОГО ЛЕЧЕНИЯ ФИБРОМИАЛГИИ

В настоящем изобретении описан способ профилактики и/или терапевтического лечения фибромиалгии, заключающийся в применении противофибромиалгического средства и другого фармацевтического действующего вещества для образования лекарственной комбинации, при этом противофибромиалгическое средство наряду с фармацевтически приемлемыми вспомогательными веществами содержит действующее вещество на основе хинина в виде хинина или по меньшей мере одной его соли, а другое фармацевтическое действующее вещество представлено анальгетиком или антидепрессантом и действующее вещество на основе хинина рассчитано на введение в организм в исходной суточной дозе от 100 до 1000 мг с последующим уменьшением до поддерживающей суточной дозы, сниженной на 20-80% относительно исходной суточной дозы, в каждом случае из расчета на хинин.

ПРИМЕНЕНИЕ УСИЛИВАЮЩИХ АГЕНТОВ, ВОЗМОЖНО СВЯЗАННЫХ С РИБОФЛАВИНОМ, А ТАКЖЕ СООТВЕТСТВУЮЩИХ ОФТАЛЬМОЛОГИЧЕСКИХ КОМПОЗИЦИЙ ДЛЯ ПЕРЕКРЕСТНОГО СШИВАНИЯ РОГОВИЦЫ ПРИ ЛЕЧЕНИИ КЕРАТОКОНУСА ИЛИ ДРУГИХ ЭКТАЗИЙНЫХ РАССТРОЙСТВ РОГОВИЦЫ

В данном документе описано применение усиливающих агентов возможно с рибофлавином, а также соответствующих композиций для лечения кератоконуса или других эктазийных расстройств роговицы при помощи способа перекрестного сшивания роговицы.

METHOD FOR RADIOCHEMOTHERAPY OF DISSEMINATED BREAST CANCER USING TAXANES

СОЕДИНЕНИЯ С СУЛЬФАМИДНОЙ ГРУППОЙ И СОДЕРЖАЩИЕ ЭТИ СОЕДИНЕНИЯ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ

В заявке описываются соединения, которые в качестве пролекарства и/или носителя обеспечивают возможность абсорбции (поглощения) активного вещества эритроцитами и/или связывание активного вещества с эритроцитами, при этом абсорбция указанных соединений эритроцитами и/или связывание этих соединений с эритроцитами осуществляется благодаря наличию группы -SO2NR1R2, в которой R1 и R2 независимо друг от друга обозначают атом водорода, ацильную группу, алкильную группу, циклоалкильную группу, арильную группу, цианогруппу или гидроксигруппу. Предлагаемое в изобретении пролекарство позволяет придать таким активным веществам, как присутствующие в живом организме вещества, природные вещества и синтетические вещества, обладающим ценными терапевтическими свойствами, способность для их целенаправленного перорального применения с высокой эффективностью уже при первом введении ("эффект первого прохождения"), соответственно повысить решающим образом их пероральную активность. Отчет о международном поиске ...

СПОСОБ ВОССТАНОВЛЕНИЯ ПОВРЕЖДЕННОЙ СТРУКТУРЫ ВОЛОС ПО ИНДРИКСОНУ-ЧАКИЮ

Изобретение относится к области медицины, в частности к дерматологии, косметологии и трихологии, и может быть применено для восстановления поврежденной структуры волос. Способ по изобретению предусматривает нанесение на волосы смеси репейного масла, цистеина, экстракта хинина и витаминов В5, В6, В8, ее контакта с волосами в течение 40 минут, мытье волос обычным шампунем и сушку, при этом такую ​​процедуру повторяют 1-2 раза в течение недели до достижения положительного эффекта.

НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ КОНЦЕПЦИИ ЛЕЧЕНИЯ ФИБРОМИАЛГИИ

В заявке описаны новые концепции профилактики и/или терапевтического лечения встречающихся в медицине или ветеринарии заболеваний, вызванных нарушением регуляции проведения болевого раздражения, соответственно поддающихся лечению путем подавления проведения болевого раздражения, прежде всего фибромиалгии.

СПОСІБ ЛІКУВАННЯ ЗАРАЗНИХ ФОРМ СИФІЛІСУ

Спосіб лікування заразних форм сифілісу шляхом традиційної антибіотикотерапії включає використання імуномодуляторів, що впливають на визначені ланки імунітету. Застосовують імуномодулюючий, антикоагулянтний, протизапальний, антипроліферативний препарат "Манакс" перорально, кожен день по 90 мг, три рази на добу, загальним курсом 30 - 60 днів.

НОВІ ПОХІДНІ 2-(ІМІНОМЕТИЛ)АМІНО-ФЕНІЛУ, ЇХ ОТРИМАННЯ, ЗАСТОСУВАННЯ ЯК ЛІКІВ, ТА ФАРМАЦЕВТИЧНІ КОМПОЗИЦІЇ, ЩО ЇХ МІСТЯТЬ

Винахід стосується нових похідних 2-(імінометил)амінофенілу, їх отримання, застосування як ліків, та фармацевтичних композицій, що їх містять.

ПРИМЕНЕНИЕ БИОУСИЛИВАЮЩИХ АГЕНТОВ ПРИ ПЕРЕКРЕСТНОМ СШИВАНИИ РОГОВИЦЫ

Изобретение относится к области офтальмологии. Согласно изобретению предложено применение одного или нескольких биоусиливающих агентов, выбранных из ЭДТА (этилендиаминтетрауксусной кислоты), связанной с трометамином, полисорбата 80, трометамина, взятых по одному или смешанных вместе, для изготовления офтальмологической композиции для способа перекрестного сшивания роговицы при лечении кератоконуса или других эктазийных расстройств для способствования прохождению офтальмологической композиции, содержащей рибофлавин, в строму через эпителий роговицы. Также предложены офтальмологические композиции и глазные капли, содержащие указанные выше компоненты.

Application of etacrynic acid in preparation of drugs for treatment and prevention of obesity and related metabolic diseases

Improved chemical synthesis of diazaindoles by chichibabin cyclization

An improved synthesis method for making diazaindoles using a Chichibabin cyclization is disclosed. In particular, this method is useful for making the compound of Formula I.

Pharmaceutical compositions for terminating acute episodes of cardiac arrhythmia, restoring sinus rhythm, preventing recurrence of cardiac arrhythmia and/or maintaining normal sinus rhythm in mammals

Disclosed are pharmaceutical compositions for and methods of preventing or treating acute and/or chronic cardiac arrhythmias in a mammal, including terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and/or maintaining normal sinus rhythm, which contain a combination of 1-[2-[(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine.

Chirally pure isomers of itraconazole for use as angiogenesis inhibitors

Described herein are methods of inhibiting angiogenesis, and treating and preventing disorders associated with angiogenesis by administering anti-angiogenesis compounds to a subject.

PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF DEPRESSION, ANXIETY, AND NEURODEGENERATIVE DISORDERS

Pharmaceutical compositions and methods for treating depression, anxiety, and neurodegenerative diseases and cognitive disorders, such as dementia and Alzheimer's disease, by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine. 1. A method for treating depression , comprising:administering from about 10 mg to about 200 mg of dextromethorphan per day in combination with from about 1 mg to less than about 50 mg of quinidine per day to a patient in need thereof.2. The method of claim 1 , wherein from about 10 mg to about 45 mg of quinidine is administered per day claim 1 , and wherein from about 20 mg to about 60 mg of dextromethorphan is administered per day.3. The method of claim 1 , wherein the quinidine is in a form of quinidine sulfate and wherein the dextromethorphan is in a form of dextromethorphan hydrobromide.4. The method of claim 1 , wherein quinidine and dextromethorphan are administered in a unit dosage form comprising about 45 mg dextromethorphan hydrobromide and about 10 mg quinidine sulfate.5. The method of claim 1 , wherein quinidine and dextromethorphan are administered in a unit dosage form comprising about 30 mg dextromethorphan hydrobromide and about 10 mg quinidine sulfate.6. The method of claim 1 , wherein quinidine and dextromethorphan are administered in a unit dosage form comprising about 20 mg dextromethorphan hydrobromide and about 10 mg quinidine sulfate.7. The method of claim 1 , wherein quinidine and dextromethorphan are administered in a unit dosage form comprising about 15 mg dextromethorphan hydrobromide and about 10 mg quinidine sulfate.8. The method of claim 1 , wherein quinidine and dextromethorphan are administered in a unit dosage form comprising about 10 mg dextromethorphan hydrobromide and about 10 mg quinidine sulfate.9. The method of claim 1 , wherein quinidine and dextromethorphan are administered in a unit dosage form configured for administration once a day claim 1 , ...

Process for making sterile aripiprazole of desired mean particle size

A process is provided for making sterile aripiprazole having an average particle size less than 100 microns but preferably greater than 25 microns employing an impinging jet crystallization procedure. The resulting bulk aripiprazole of desired particle size may be used to form a sterile freeze-dried aripiprazole formulation, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks.

Taste masked dosage forms of bitter tasting anti-retroviral drugs

The present invention relates to taste masked dosage forms of bitter tasting anti-retroviral drugs comprising a complex of the said anti-retroviral drug and an ion-exchange resin and one or more of other pharmaceutically acceptable excipients. It further relates to the processes for the preparation thereof.

Triazolopyrazinones as p2x7 receptor antagonists

The invention provides certain 3,7-disubstituted-[1,2,4]triazolo[4,3-a]pyrazin-8(7H)-ones of the Formula (I), and their pharmaceutically acceptable salts, wherein R 1 , R 2 , R 3 , R 8 , and X are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating pain or an inflammatory disease.

Method for treating pulmonary arterial hypertension in a patient not having idiopathic pulmonary fibrosis

There is provided a method of treating pulmonary hypertension in a patient in need thereof, said method comprising: administering a therapeutically effective amount of ambrisentan to the patient with pulmonary arterial hypertension, wherein the patient has been determined not to have idiopathic pulmonary fibrosis.

Combination therapy with parp inhibitors

The present invention describes benzimidazole derivatives of Formula (I) which constitute potent PARP inhibitors in combination with radiotherapy or in combination with other chemotherapeutic agents.

Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof

This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly FGFR2 variants, which are linked to drug resistance. The disclosure further provides methods of diagnosis and theranosis, using these molecules and fragments thereof, and kits for employing these methods and compositions.

Quinoxaline compound

The present inventors have investigated a compound which has a PDE9-inhibitory action and is useful as an active ingredient for an agent for treating and/or preventing storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like, and thus, have found that an imidazoquinoxaline compound or a triazoloquinoxaline compound has a PDE9-inhibitory action, thereby completing the present invention.

Treatment of Vasomotor Symptoms

The invention relates to a method for the treatment of vasomotor symptoms comprising the administration of a therpeutically effective amount of flibanserin.

Patch preparation

A patch preparation containing a support and an adhesive layer formed on one surface of the support, wherein the adhesive layer contains 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine or a physiologically acceptable acid addition salt thereof, an acrylic polymer, lactic acid, sesame oil and one or more kinds of stabilizers selected from 2-mercaptobenzimidazole, 2,6-di-tert-butyl-4-methylphenol and propyl gallate. A patch preparation containing a support and an adhesive layer containing lactic acid and magnesium aluminometasilicate and formed on at least one surface of the support, which preparation is superior in both skin permeability and adhesiveness in the presence of water.

TRPM5 INHIBITORS SUPPORT BODY WEIGHT REDUCTION WITHOUT REDUCING FOOD INTAKE

The present invention relates to the field of weight management and the prevention and/or treatment of metabolic disorders. In particular, the present invention provides a composition comprising at least one Trpm5 inhibitor which is effective in the treatment of prevention of metabolic disorders or risk factors thereof, such as overweightness or obesity, without having to reduce food intake below metabolic needs. 1. A method for use in the treatment of prevention of metabolic disorders without reducing food intake comprising administering a composition comprising at least one Trpm5 inhibitor to an individual in need of same.2. Method according to for use in supporting weight loss and/or weight maintenance in humans and/or animals.3. Method according to for use in the treatment of overweightness or obesity.4. Method according to claim 1 , wherein the Yo-yo effect is avoided.5. Method according to for use in the reduction of fat mass.6. Method according to claim 1 , wherein the metabolic disorders are selected from the group consisting of diabetes claim 1 , hypertension and cardiovascular diseases.7. Method according to claim 1 , wherein the composition is selected from the group consisting of food compositions claim 1 , nutritional compositions claim 1 , nutraceuticals claim 1 , powdered nutritional products to be reconstituted in water or milk before consumption claim 1 , food additives claim 1 , medicaments claim 1 , drinks claim 1 , and pet food.8. Method according to claim 1 , wherein the Trpm5 inhibitor is quinine ((R)-(6-methoxyquinolin-4-yl)((2S claim 1 ,4S claim 1 ,8R)-8-vinylquinuclidin-2-yl)methanol.9. Method according to claim 1 , wherein the Trpm5 inhibitor is quinine hydrochloride10. Method according to claim 1 , wherein the Trpm5 inhibitor is quinine sulphate.11. Method according to comprising Trpm5 inhibitor in an amount of at least 0.1 mg/kg of the composition.12. Method according to to be administered in an amount corresponding to at least 0.003 mg ...

Apparatus and method for cryogranulating a pharmaceutical composition

Cryogranulation systems with improved dispenser assemblies are provided for use in manufacturing frozen pellets of pharmaceutical substances in a fluid medium. Methods of cryogranulating the pharmaceutical substance in the fluid medium are also provided. In particular embodiments, the dispenser assembly is used with suspensions or slurries of pharmaceutical compositions including biodegradable substances, such as proteins, peptides, and nucleic acids. In certain embodiments, the pharmaceutical substance can be adsorbed to any pharmaceutically acceptable carrier particles suitable for making pharmaceutical powders. In one embodiment, the pharmaceutical carrier can be, for example, diketopiperazine-based microparticles. The dispenser assembly improves the physical characteristics of the cryopellets formed and minimizes product loss during processing.

Novel fluoroergoline analogs

Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT 1D and/or the 5-HT 1B receptor, without agonizing the 5-HT 2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha 2A and/or the alpha 2B receptors using the compounds and compositions disclosed herein.

GLUTAMATE RELEASE FROM ASTROCYTE

The present invention investigate the two modes of glutamate release and the releasing rate of glutamate, and thus can provide a useful technique for neuron protection and acceleration of neurotransmission by controlling the glutamate release in astroctye. Thus, the present invention provides an inhibitor of the fast-mode release and/or the slow-mode release of astrocytic glutamate, a screening method of the inhibitor and a pharmaceutical composition or method of ameliorating, preventing and/or treating the disease associated with the over-release of glutamate via the Ca-activated anion channel, with the inhibition of fast-mode glutamate release. 1. A glutamate-release inhibitor , which is adapted for inhibition of glutamate release from an astrocyte in non-vesicular and channel-mediated mode through a glutamate-permeable potassium channel or Ca-activated anion channel in the astrocyte.2. The glutamate-release inhibitor of claim 1 , wherein the potassium channel is TREK-1 channel claim 1 , or Ca-activated anion channel is Bestrophin-1 channel.3. The glutamate-release inhibitor of claim 1 , wherein the inhibitor is at least an inhibitor of potassium channel selected from the group consisting of the inhibitors of activation of G protein-coupled receptor claim 1 , Gα claim 1 , activation claim 1 , Gα-Gdissociation claim 1 , binding of Gto N-terminus of TREK-1 claim 1 , and opening of the potassium channel in the astrocyte.4. The glutamate-release inhibitor of claim 3 , wherein the potassium channel-mediated mode is a fast-mode release of glutamate where the onset current of the astrocyte measured by sniffer patch method after the treatment of an activating agent of G-protein coupled receptor claim 3 , ranges 50 to 400 ms.5. The glutamate-release inhibitor of claim 3 , wherein the inhibitor of potassium channel is at least one selected from the group consisting of Quinine claim 3 , TREK-1-shRNA consisting of the nucleotide sequence of SEQ ID NO:1 claim 3 , a peptide ...

Nasal dosage forms of dihydroergotamine

The present application relates to a nasal dosage form of dihydroergotamine, wherein said dosage form requires less than about 15 minutes for administration and requires less than four sprays to administer effective dose of dihydroergotamine for treating migraine in human subjects.

Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis

Pharmaceutical compositions of the invention include substituted riluzole pro drugs useful for the treatment of amyotrophic lateral sclerosis (ALS) and related disorders through the release of riluzole, especially to avoid patient to patient variability in first pass, hepatic metabolism promoted by Cyp 1A2. Pro-drugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process. The invention further includes pro-drugs of riluzole useful for the treatment of disease states that can be treated with riluzole through the release of riluzole from a pro-drug agent.

Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts

Processes are disclosed for making vortioxetine and pharmaceutically acceptable salts thereof. A propylene glycol solvate of vortioxetine hydrobromide is disclosed. A novel crystalline form of vortioxetine hydrobromide propylene glycol solvate, designated form AC1, is disclosed along with a method for making same. Form AC1 may be characterized by an x-ray powder diffraction pattern with peaks at about 19.64, 22.85, 25.51, 29.57, 30.18±0.2 degrees 2-theta.

PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF DEPRESSION, ANXIETY, AND NEURODEGENERATIVE DISORDERS

Pharmaceutical compositions and methods for treating depression, anxiety, and neurodegenerative diseases and cognitive disorders, such as dementia and Alzheimer's disease, by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine. 1. A method for treating depression , comprising:administering from about 10 mg to about 200 mg of dextromethorphan per day in combination with from about 1 mg to less than about 50 mg of quinidine per day to a patient in need thereof.2. The method of claim 1 , wherein from about 10 mg to about 45 mg of quinidine is administered per day claim 1 , and wherein from about 20 mg to about 60 mg of dextromethorphan is administered per day.3. The method of claim 1 , wherein the quinidine is in a form of quinidine sulfate and wherein the dextromethorphan is in a form of dextromethorphan hydrobromide.4. The method of claim 1 , wherein quinidine and dextromethorphan are administered in a unit dosage form comprising about 45 mg dextromethorphan hydrobromide and about 10 mg quinidine sulfate.5. The method of claim 1 , wherein quinidine and dextromethorphan are administered in a unit dosage form comprising about 30 mg dextromethorphan hydrobromide and about 10 mg quinidine sulfate.6. The method of claim 1 , wherein quinidine and dextromethorphan are administered in a unit dosage form comprising about 20 mg dextromethorphan hydrobromide and about 10 mg quinidine sulfate.7. The method of claim 1 , wherein quinidine and dextromethorphan are administered in a unit dosage form comprising about 15 mg dextromethorphan hydrobromide and about 10 mg quinidine sulfate.8. The method of claim 1 , wherein quinidine and dextromethorphan are administered in a unit dosage form comprising about 10 mg dextromethorphan hydrobromide and about 10 mg quinidine sulfate.9. The method of claim 1 , wherein quinidine and dextromethorphan are administered in a unit dosage form configured for administration once a day claim 1 , ...

Methods for Treating HCV

The present invention features interferon-free therapies for treating HCV genotype 1b, 2, 3 or 4. In one aspect, the therapies comprise administering Compound 1, ritonavir, and Compound 2 to a subject infected with HCV genotype 1b or 4, wherein the therapies do not include administration of any interferon, and the therapies last for 12 weeks. Preferably, the therapies do not include administration of any ribavirin.

Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5.6.8.8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid

The present invention relates to a process for synthesizing a compound of formula (I), R 1 is phenyl, which is unsubstituted or substituted with one, two or three substituents independently selected from halogen and C 1-6 alkyl; R 2 is C 1-6 alkyl; R 3 is —C x H 2x —; x is 1, 2, 3, 4, 5, 6 or 7; or pharmaceutically acceptable salt or diastereomer thereof, which is useful for prophylaxis and treatment of a viral disease in a patient relating to hepatitis B infection or a disease caused by hepatitis B infection.

Methods and pharmaceutical compositions for the treatment of ebola virus disease

The invention relates to methods and pharmaceutical compositions for the treatment of Ebola Virus Disease. In particular the present relates to a method of treating Ebola Virus Disease in a subject in need thereof comprising administering the subject with a therapeutically effective amount of Favipiravir.

Pain Medicine Combination and Uses Thereof

Embodiments disclosed herein describe, amongst other things, dosage forms, compounds, compositions, pharmaceutical compositions that can be used in the treatment of, for example, pain and pain related disorders or to produce analgesia. 1. A pharmaceutical composition comprising:a NMDA antagonist;a CYP2D6 inhibitor; andan opioid agonist.2. The pharmaceutical composition of claim 1 , wherein the opioid agonist is chosen from one or more of: morphine claim 1 , oxycodone claim 1 , and hydromorphone claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , or any combination thereof.3. The pharmaceutical composition of claim 1 , wherein the NMDA antagonist is chosen from one or more of dextromethorphan claim 1 , a glycine antagonist claim 1 , ifenprodil like compound claim 1 , amantadine claim 1 , MK-801 (dizocilpine; [5R claim 1 ,10S]-[+]-5-methyl-10 claim 1 ,11-dihydro-5H-dibenzo[a claim 1 ,d]cyclohepten-5 claim 1 ,10-imine) claim 1 , ketamine claim 1 , memantine claim 1 , D-AP5 (D(−)-2-Amino-5-phosphonovaleric acid) and claim 1 , CPP (3-(2-Carboxypiperazin-4-yl)propyl-1-phosphonic acid) claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , or any combination thereof.4. The pharmaceutical composition of claim 1 , wherein the NMDA antagonist is dextromethorphan claim 1 , or a pharmaceutically acceptable salt thereof.5. The pharmaceutical composition of claim 1 , wherein the NMDA antagonist is dextromethorphan hydrobromide monohydrate.6. The pharmaceutical composition of claim 1 , wherein the CYP2D6 inhibitor is chosen from one or more of: quinidine claim 1 , bupropion claim 1 , cinacalcet claim 1 , fluoxetine claim 1 , paroxetine claim 1 , duloxetine claim 1 , sertraline claim 1 , terbinafine claim 1 , amiodarone claim 1 , and cimetidine claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , or any combination thereof.7. The pharmaceutical composition of claim 1 , wherein the CYP2D6 inhibitor is quinidine claim 1 , or a pharmaceutically ...

Rbp4 antagonists for the treatment of age-related macular degeneration and stargardt disease

A method for treating a disease characterized by excessive lipofuscin accumulation in the retina in a mammal afflicted therewith, comprising administering to the mammal an effective amount of a compound having the structure of any one of Formulas I-IV described herein, or a pharmaceutically acceptable salt thereof.

Process for preparing soluble guanylate cyclase stimulators

The invention relates to novel methods for preparing 3-substituted 1,2,4-triazole compounds as sGC stimulators and their synthetic precursors.

Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bruton's tyrosine kinase

In some embodiments, the present invention relates to novel small molecule inhibitors that block the CXCR4-SDF-1 signaling pathway by directly inhibiting members of the Tec family of kinases, namely Bruton's tyrosine kinase (BTK), and their use in treating diseases in which pathogenesis is mediated by the CXCR4/SDF-1 signaling pathway.

Compositions and Methods for Treating an Active Mycobacterium Tuberculosis Infection

The present disclosure relates to methods and compositions for treating a active tuberculosis infection and methods and compositions for improving the efficacy of chemotherapy regimens against active tuberculosis infection. The present disclosure relates to methods of treating an active M. tuberculosis infection or an active infection resulting from reactivation of a latent infection in a mammal and to methods of improving the efficacy of chemotherapy regimens against active M. tuberculosis infection.

Treatments for diabetic symmetrical polyneuropathy

Treatments for therapy of a diabetic symmetrical polyneuropathy a subject in need thereof. The treatments includes administration of compositions comprising: an effective amount of a muscarinic acetylcholine receptor antagonist exemplified by pirenzepine, telenzepine, atropine, or derivatives thereof or salts thereof or analogs thereof or derivatives thereof, and a pharmacologically acceptable carrier. The composition may be injectable or alternatively, may be applied topically or alternatively, may be delivered orally. A suitable topical composition may comprise a lotion, a cream, a gel, or a viscous fluid. The muscarinic acetylcholine receptor antagonist may be a muscarinic acetylcholine receptor antagonist salt or a muscarinic acetylcholine receptor antagonist derivative or a muscarinic acetylcholine receptor antagonist analog.

Liquid oral formulations for pde v inhibitors

The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.

Antiviral activity of tyrosine kinase inhibitors against hepatitus c virus

Antiviral activity of Nilotinib against Hepatitis C virus.

Targeting parp1 for treatment of tsc and cancers

The present invention relates to methods of treating a condition associated with mTORC1 hyperactivation or TSC2-deficient cancer, the method comprising administering to a subject having the cancer a pharmaceutically-effective amount of a poly(ADP-ribose) polymerase 1 (PARP1) inhibitor. In some embodiments, the condition associated with mTORC1 hyperactivation is tuberous sclerosis complex (TSC). In some embodiments, the condition associated with mTORC1 hyperactivation is lymphangioleiomyomatosis (LAM). In some embodiments, the condition associated with mTORC1 hyperactivation is TSC2-deficient cancer.

Method of using flibanserin for neuroprotection

The present invention relates to the use of 1-[2-(4-(3-trifluoromethyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one, optionally in the form of its pharmaceutically acceptable acid addition salts and optionally in the form of its hydrates or solvates, for preparing a pharmaceutical composition with a neuroprotective activity.

Ophthalmic formulations for the treatment of presbyopia

The disclosure relates to a pharmaceutical formulation comprising a nanoparticle composition that provides controlled delivery of one or a combination of therapeutic agents. Additionally, the disclosure relates to a pharmaceutical formulation comprising a plurality of coated nanoparticles, wherein the coated nanoparticle comprises a core particle comprising a solid pharmaceutical agent or salt thereof. The disclosure further relates to methods of treating one or more ophthalmic conditions or diseases comprising administering a therapeutically effective amount of a disclosed pharmaceutical formulation.

Isoquinoline amide and isoquinoline amide-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction

Compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.

Lsd1 inhibitors as skeletal muscle hypertrophy inducers

The present invention relates to LSD/ inhibitors and their uses as skeletal muscle hypertrophy inducers as well as to promote skeletal muscle regeneration, to prevent skeletal muscle atrophy, or in the treatment or prevention of a disease or injury resulting in loss of skeletal muscle tissue and/or muscle weakness. It further relates to the non-therapeutic use of such compounds to increase muscle mass, muscle strength and/or muscle performance in a subject.

Pharmaceutical dosage forms comprising a low-solubility drug and a polymer

A dosage form comprises a low-solubility drug, and a precipitation-inhibiting polymer. The drug is in a solubility-improved form and in the form of particles at least partially coated with the precipitation-inhibiting polymer.

Multimeric forms of antimicrobial peptides

The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3. The method includes a composition or combination comprising the multimeric antimicrobial peptides and at least one active pharmaceutical ingredient.

Pharmaceutical composition for treating posttraumatic stress disorder

Provided are a posttraumatic stress disorder (PTSD) animal model in which dopamine receptor subtype 4 (D4R) is damaged or deficient, a method for preparing the same, a method for screening a drug for treating PTSD using the same, and a pharmaceutical composition for treating PTSD comprising a drug detected by the screening method. As it is identified that a specific type of dopamine receptor is associated with a mechanism for fear memory expression induced by long-term depression (LTD), the understanding of pathogenesis of PTSD may be heightened, the animal model exhibiting similar clinical conditions of PTSD and the method for preparing the same may be applied in analyses for stability and effectiveness of a therapeutic agent for PTSD and screening of a therapeutic drug. Further, an agonist of D4R contained in the composition has been approved by the US FDA and clinically used for psychiatric diseases such as schizophrenia, and thus may be immediately used for clinical applications for PTSD symptoms.

Compositions & methods for lowering intraocular pressure

Disclosed herein are compositions for lowering intraocular pressure (IOP) of an eye comprising a combination IOP-lowering agents bimatoprost, brimonidine, and timolol. Further disclosed are methods for reducing IOP in the eye of a subject.

Stable pharmaceutical composition of Selexipag

A stable pharmaceutical composition of Selexipag is provided that includes a Selexipag-Mannitol pre mix and excipients. The present application relates to stable pharmaceutical compositions that include Selexipag which are suitable for oral administration. In particular, the application relates to pharmaceutical compositions of Selexipag in which acid impurity is less than 1% w/w. The application also relates to processes for making such compositions and use thereof in treating patients with pulmonary arterial hypertension.

TREATMENT OF NEURODEGENERATIVE DISEASES

Treatment of Neurodegenerative Diseases Methods for the prevention and treatment of neurodegenerative diseases, in particular motor neuron diseases such as amyotrophic lateral sclerosis (ALS), are described, as well as compositions and combined preparations for use in the methods. The methods comprise inhibiting c-Abl, and inhibiting NFκB activation, in the central nervous system of a subject in need of such prevention or treatment. The compositions comprise an inhibitor of c-Abl, and an inhibitor of NFκB activation. 1. A method of preventing or treating a motor neuron disease , which comprises inhibiting c-Abl , and inhibiting NFκB through inhibition of p38 and/or JNK MAPkinases , in the central nervous system of a subject in need of such prevention or treatment.2. A method according to claim 1 , wherein c-Abl and NFκB activation are inhibited in microglial cells claim 1 , astrocytes claim 1 , or neurons of the subject.3. A method according to or claim 1 , wherein c-Abl is inhibited so as to inhibit microglial cell activation and/or formation of inclusions of TDP43.4. A method according to claim 3 , wherein formation of inclusions of TDP43 is inhibited by inducing deacetylation of TDP43.5. A method according to any preceding claim claim 3 , wherein c-Abl inhibition reduces EGFR signaling in the subject.6. A method according to any preceding claim claim 3 , wherein c-Abl is inhibited by administering an inhibitor of c-Abl to the subject.7. A method according to claim 6 , wherein the c-Abl inhibitor is co-administered claim 6 , or administered sequentially claim 6 , to the subject with a P-glycoprotein inhibitor.8. A method according to any preceding claim claim 6 , wherein NFκB activation is inhibited so as to inhibit production of IL-1β and NFκB and/or to inhibit formation of inclusions of TDP43.9. A method according to any preceding claim claim 6 , wherein NFκB activation is inhibited by inhibiting p38 MARK.10. A method according to any preceding claim claim 6 , ...

Novel compositions and methods of preventing or ameliorating abnormal thrombus formation and cardiovascular disease

The invention includes compositions and methods useful for treating preventing abnormal thrombus formation and subsequent cardiovascular disease in diabetic patients and patients with increased cardiovascular risk.

Methods of treatment with cyp3a4 substrate drugs

The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.

Methods for using fxr agonists

The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver diseases and disorders.

Treatment of Vasomotor Symptoms

The invention relates to a method for the treatment of vasomotor symptoms comprising the administration of a therapeutically effective amount of flibanserin.

Pirfenidone therapy and inducers of cytochrome p450

The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking.

Tuberculosis Biomarkers and Uses Thereof

The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection, treatment and diagnosis of tuberculosis (TB). In one aspect, the present application includes the identification of biomarkers that can be used alone or in various combinations for the detection of TB, including those set forth in Tables 1, 2, 4, 5, and 8 to 12. In another aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose or prognose TB or follow treatment response. In another aspect, methods are provided for diagnosing TB in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Tables 1, 2, 4, 5, and 8 to 12, wherein the individual is classified as having TB, or the likelihood of the individual having TB is determined, based on the at least one biomarker value.

Pain Medicine Combination and Uses Thereof

Embodiments disclosed herein describe, amongst other things, dosage forms, compounds, compositions, pharmaceutical compositions that can be used in the treatment of, for example, pain and pain related disorders or to produce analgesia. 151-. (canceled)52. A non-sustained release pharmaceutical composition formulated for simultaneous administration consisting essentially of:dextromethorphan, or a pharmaceutically acceptable salt thereof;quinidine, or a pharmaceutically acceptable salt thereof, andmorphine, or a pharmaceutically acceptable salt thereof,wherein the ratio of morphine, or a pharmaceutically acceptable salt thereof, to dextromethorphan, or a pharmaceutically acceptable salt thereof, to quinidine, or a pharmaceutically acceptable salt thereof, is about 1:1:1 (wt:wt:wt).53. The pharmaceutical composition of claim 52 , wherein the dextromethorphan is dextromethorphan hydrobromide monohydrate.54. The pharmaceutical composition of claim 52 , wherein the quinidine is quinidine gluconate or quinidine sulfate.55. The pharmaceutical composition of claim 52 , wherein the morphine is morphine sulfate.56. The pharmaceutical composition of claim 52 , wherein the composition does not have a sequestered opioid antagonist.57. A method of treating pain in a subject in need thereof claim 52 , the method comprising administering to the subject the pharmaceutical composition of . This application claims priority to U.S. Provisional Application No. 61/774,113, filed Mar. 7, 2013, which is hereby incorporated by reference in its entirety.Embodiments described herein relate to compositions and pharmaceutical compositions that can be used to treat or prevent pain or to produce analgesia.Pain is the most common symptom for which patients seek medical advice and treatment. Pain can be acute or chronic. While acute pain is usually self-limited, chronic pain, which can persist for 3 months or longer and can lead to significant changes in a patient's personality, lifestyle, ...

Apparatus and method for cryogranulating a pharmaceutical composition

Cryogranulation systems with improved dispenser assemblies are provided for use in manufacturing frozen pellets of pharmaceutical substances in a fluid medium. Methods of cryogranulating the pharmaceutical substance in the fluid medium are also provided. In particular embodiments, the dispenser assembly is used with suspensions or slurries of pharmaceutical compositions including biodegradable substances, such as proteins, peptides, and nucleic acids. In certain embodiments, the pharmaceutical substance can be adsorbed to any pharmaceutically acceptable carrier particles suitable for making pharmaceutical powders. In one embodiment, the pharmaceutical carrier can be, for example, diketopiperazine-based microparticles. The dispenser assembly improves the physical characteristics of the cryopellets formed and minimizes product loss during processing.

Ergoloid for Cancer

A drug developed to treat dementia which has been abandoned by its manufacturer, Novartis, is repurposed to enhance the treatment of cancer. The drug, Ergoloid, contains four gamma secretase inhibitors that produce the same benefit as single gamma secretase inhibitors that are in clinical trials to enhance the treatment of cancer. The method of this invention is to administer Ergoluid 1 mg three times a day by mouth. This enhancement results in better outcomes with lower cost and better quality of life.

SNACK SYSTEM, INCLUDING INTERIOR FILING OF INGREDIENT, OUTER COATING OF INGREDIENT, ADDITION OF INGREDIENT, AND FORMATION OF SNACK ROLL

A novel snack system is created in various form, variety, and with various ingredient. The snack system is created being a snack, with at least one ingredient, and at least one texture. The category of snack includes cheese, powdery candy, soft candy, creamy candy, gummy candy, hard candy, liquid candy, fudge candy, chocolate, ice cream, ice milk, sherbet, gelato, yogurt, sorbet, tofu, jelly, pudding, chewing gum, roll, pie, biscuit, cookie, donut, pastry, cake, pancake, crepe, waffle, bread, tortilla, and taco. The snack can be served at room temperature, cold from refrigerator, warm, hot, and reheated. The snack is in form selected from group consisting of interior filing of ingredient, outer coating of ingredient, and formation of snack roll. The snack is also created with addition of various ingredients. The snack is created with at least one ingredient selected from group consisting of flavoring ingredient, nutritional ingredient, health ingredient, and other ingredient. 1. A snack system comprising:a snack, withat least one ingredient, andat least one texture;wherein said snack including category is selected from group consisting of cheese, powdery candy, soft candy, creamy candy, gummy candy, hard candy, liquid candy, fudge candy, chocolate, ice cream, ice milk, sherbet, gelato, yogurt, sorbet, tofu, jelly, pudding, chewing gum, roll, pie, biscuit, cookie, donut, pastry, cake, pancake, crepe, waffle, bread, tortilla, and taco;wherein said snack is selected from group consisting of caffeinated, and non caffeinated;wherein said snack is selected from group consisting of diet, and non diet;wherein said snack can be uncooked;wherein said snack can be cooked by method selected from group consisting of deep frying, sun drying, roasting, baking, boiling, steaming, grilling, and frying;wherein said snack is served in manner selected from group consisting of room temperature, cold from refrigerator, warm, hot, and reheated;wherein said snack comprising sugar can ...

NON-INFECTIVE NASAL SYMPTOM MANAGEMENT COMPOSITIONS AND METHODS

A method of managing non-infective nasal symptoms may include formulating a topical composition for nasal administration. The formulation may include combining about 0.25 mg to about 2 mg budesonide, about 50 mg to about 650 mg quinine sulfate, and a diluent. The topical composition may be administered nasally via irrigation or nebulization. 1. A method of managing non-infective nasal symptoms , the method comprising:formulating a topical composition for nasal administration comprising:combining about 0.25 mg to about 2 mg budesonide, about 50 mg to about 650 mg quinine sulfate, and a diluent.2. The method of claim 1 , further comprising combining poloxamers and xylitol with the budesonide claim 1 , quinine sulfate claim 1 , and diluent.3. The method claim 1 , wherein the diluent comprises distilled water.4. The method of claim 1 , wherein the quinine sulfate is combined in an amount between about 100 mg and about 324 mg.5. The method of claim 1 , wherein the budesonide is combined in an amount about 0.5 mg claim 1 , about 1 mg claim 1 , or about 2 mg.6. The method of claim 5 , wherein combining comprises combining contents of one or more budesonide 0.5 mg-2 ml vials and/or one or more budesonide 1 mg-2 ml vials.7. The method of claim 1 , wherein combining comprises combining contents of one or more commercially available quinine sulfate capsules.8. The method of claim 1 , wherein combining comprises combining contents of one or more compounded quinine sulfate capsules.9. The method of claim 1 , further comprising nasally administering the topical composition to a nasal cavity of a subject via irrigation or nebulization.10. The method of claim 1 , wherein combining comprising combining contents of one or more budesonide 0.5 mg-2 ml vials and/or a budesonide 1 mg-2 ml vials with contents of one or more commercially available quinine sulfate capsules claim 1 , and wherein the budesonide is combined in an amount of about 0.5 mg claim 1 , about 1 mg claim 1 , or about 2 ...

Muscarinic acetylcholine m1 receptor antagonists

Provided herein are compounds which are useful as antagonists of the muscarinic acetylcholine receptor M1 (mAChR M1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.

System and method for obtaining metadata about content stored in a repository

At least one of the embodiments described herein relate generally to a method of obtaining metadata for content stored in a first repository. The method may be performed at a second repository, and may include the acts of identifying a content object stored in the first repository, the content object comprising learning content usable in an electronic educational system to provide electronic learning; identifying metadata for the content object stored in the first repository, the metadata associated with the learning content of the content object; retrieving the metadata associated with the learning content from the first repository; and storing a harvested content object corresponding to the content object, wherein the harvested content object includes the metadata associated with the learning content of the content object stored in the first repository.

Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis

Pharmaceutical compositions of the invention include substituted riluzole pro drugs useful for the treatment of amyotrophic lateral sclerosis (ALS) and related disorders through the release of riluzole, especially to avoid patient to patient variability in first pass, hepatic metabolism promoted by Cyp 1A2. Pro-drugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process. The invention further includes pro-drugs of riluzole useful for the treatment of disease states that can be treated with riluzole through the release of riluzole from a pro-drug agent.

Method

The present invention relates to a method of treating pain in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate: wherein Q is as defined herein.

Targeting wnk1 in blood cancers

The present invention relates to lysine deficient protein kinase 1 (WNK1) inhibitors for use in treating patients with blood cancers, in particular leukemia and multiple myeloma.

Ophthalmic pharmaceutical composition containing a combination of brinzolamide and brimonidine and method of preparation thereof

The present invention relates to an ophthalmic aqueous composition for the decrease of intraocular pressure in patients with ocular hypertension or open angle glaucoma containing a combination of Brinzolamide and Brimonidine and a method for preparation thereof. The invention as currently presented has a significant advantage over ophthalmic compositions already known in the art. More particularly the present invention relates to a multi-dose ophthalmic aqueous composition comprising a borate, a single polyol and benzalkonium chloride as an antimicrobial agent.

Liquid oral formulations for tadalafil

The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.

COPOLYMERS INCLUDING CINCHONA ALKALOID COMPONENTS AND ONE OR MORE ACRYLAMIDE OR ACRYLATE CONTAINING COMPONENTS, COMPLEXES CONTAINING THE SAME, AND METHODS OF USING THE SAME

Copolymers polymerized from at least one or more cinchona alkaloid containing compounds; and an acrylamide containing monomer, an acrylate containing monomer, or combinations thereof. Complexes and methods utilizing such copolymers are also disclosed. 1. A copolymer polymerized from at least:one or more cinchona alkaloid containing compounds; andan acrylamide containing monomer, an acrylate containing monomer, or combinations thereof.2. The copolymer according to claim 1 , wherein the cinchona alkaloid containing compound is selected from quinine claim 1 , cinchonidine claim 1 , quinidine claim 1 , quiniline claim 1 , derivatives thereof claim 1 , or combinations thereof.3. The copolymer according to claim 1 , wherein the acrylamide containing monomer is selected from acrylamide (Am) claim 1 , (2-hydroxyethyl)acrylamide (HEAm) claim 1 , N-isopropyl acrylamide (NIPAm) claim 1 , N claim 1 ,N-Dimethyl acrylamide (DMAm) claim 1 , methyl acrylate (MA) claim 1 , or combinations thereof.4. The copolymer according to claim 1 , wherein the acrylate containing monomer is selected from (2-hydroxyethyl) acrylate (HEA).5. The copolymer according to claim 1 , wherein the copolymer is selected from the group consisting of: poly(HEA-co-quinine) claim 1 , poly(Am-co-quinine) claim 1 , and poly(HEAm-co-quinine).6. A method of forming a copolymer-genetic component complex comprising the steps of:combining one or more cinchona alkaloid containing compounds with at least an acrylamide containing monomer, an acrylate containing monomer, or combinations thereof to form a copolymer; andcombining the copolymer with at least one genetic component to form a copolymer-genetic component complex7. The method according to claim 6 , wherein the cinchona alkaloid containing compound is selected from quinine claim 6 , cinchonidine claim 6 , quinidine claim 6 , quiniline claim 6 , derivatives thereof claim 6 , or combinations thereof.8. The method according to claim 6 , wherein the acrylamide ...

Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds

The present invention relates to the compound of the formula: or pharmaceutically acceptable salts thereof, as well as compositions containing the same, processes for the preparation of the same, and therapeutic methods of use therefore in promoting hydration of mucosal surfaces and the treatment of diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, acute and chronic bronchitis, cystic fibrosis, emphysema, and pneumonia.

Bcl6 inhibitors as anticancer agents

The invention provides compositions and methods for blocking the BCL6 BTB domain with small molecule, non-peptide compounds as disclosed and claimed herein. BCL6 is a transcriptional repressor of the BTB-POZ (brie a brae, tramtrack, broad complex/pox virus zincfinger) family of proteins. It is required for normal development of germinal center (GC) B-cells and is also the most commonly involvedoncogene in diffuse large B-celllymphomas (DLBCLs), and constitutive expression of BCL6 in GC B-cells causes DLBCL in mice.

Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection

Methods of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection are disclosed.

Methods For Treating Inflammatory Conditions

The present invention relates to compounds and pharmaceutically acceptable salts thereof and formulations comprising tenilsetam or pharmaceutically acceptable salts thereof that are useful in modulating inflammation. In particular, the compounds or pharmaceutically acceptable salts thereof are useful for treating or preventing a disease or disorder involving inflammation, including, but not limited to, delayed type hypersensitivity and contact hypersensitivity.

Vigor enhancement via administration of pyrimidine derivatives

Disclosed herein are methods for increasing the overall vigor of a subject, and/or vigor of target tissues of a subject. Exemplified herein is the utilization of pyrimidine derivatives which act to stimulate stem cell proliferation. In addition to increasing vigor, such stem cell proliferation agents (SCPA) may be used to enhance and/or improve the outcome of other therapies, and may be used in psychiatric applications. Increasing vigor in subjects is not necessarily targeted to the treatment of a disease, thus, the methods can include administration to clinically healthy animals.

Inhibition of delta-6 desaturase for the treatment of cardiometabolic disease

Systems and methods for screening whether a candidate compound inhibits delta-6 desaturase activity are disclosed. Also disclosed is a transgenic mammal which overexpresses a gene encoding delta-6 desaturase and an animal model of a cardiometabolic disorder or disease that includes the transgenic mammal. A method of treating a cardiometabolic disorder or disease is also disclosed.

Compositions and methods for treating an active mycobacterium tuberculosis infection

The present disclosure relates to methods and compositions for treating a active tuberculosis infection and methods and compositions for improving the efficacy of chemotherapy regimens against active tuberculosis infection. The present disclosure relates to methods of treating an active M. tuberculosis infection or an active infection resulting from reactivation of a latent infection in a mammal and to methods of improving the efficacy of chemotherapy regimens against active M. tuberculosis infection.

Anti-tuberculosis stable pharmaceutical composition in a form of a dispersible tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation

The present invention relates to an oral pharmaceutical fixed dose composition in a form of a dispersible tablet for use in the treatment of tuberculosis, said oral pharmaceutical composition comprising: a) granules comprising isoniazid and at least one intragranular excipient, b) granules comprising rifapentine and at least one intragranular excipient, and c) at least one extragranular excipient, and to its process of preparation.

3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof

Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Increasing parkin activity by administering a deubiquitinating enzyme inhibitor

Provided herein are methods of promoting parkin activity in a subject, comprising: selecting a subject with a disorder associated with decreased Parkin activity; and administering to the subject an effective amount of a composition that increases parkin activity, wherein the composition is an inhibitor of a deubiquitinating enzyme.

Stereochemically enriched compositions for delivery of nucleic acids

Provided, in part, is a composition comprising one or more chemical entities of formula I, each of which is a compound of formula I: a pharmaceutically acceptable salt thereof, a solvate thereof, or a solvate of a pharmaceutically acceptable salt thereof, the composition characterized in that greater than a first threshold amount of the total amount of chemical entities of formula I in the composition: are chemical entities of formula I.a, wherein the first threshold amount is 50%; or are chemical entities of formula I.b.1, wherein the first threshold amount is 25%; or are chemical entities of formula I.b.2, wherein the first threshold amount is 25%, wherein the chemical entities of formula I.a, I.b.1, and I.b.2, are described herein, and methods of using such compositions, for example, for the delivery of a polynucleotide in vivo.

METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS WITH PRIDOPIDINE

Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine as monotherapy or together with riluzole, edaravone, combination of dextromethorphan/quinidine, sodium phenylbutyrate (PB), tauroursodeoxycholic acid or combination of sodium phenylbutyrate (PB)/tauroursodeoxycholic acid (i.e. AMX0035) as combination or add-on therapy. 1. A method for treating a subject afflicted with amyotrophic lateral sclerosis (ALS) , comprising periodically administering to the subject an amount of pridopidine effective to treat the subject.2. The method of claim 1 , wherein the ALS is sporadic ALS.3. The method of claim 1 , wherein the amount of pridopidine is effective to inhibit or reduce progression of a symptom of the ALS in the subject.4. The method of claim 3 , where in the symptom is muscles stiffness claim 3 , muscle weakness claim 3 , muscle wasting claim 3 , muscle cramps claim 3 , difficulty speaking claim 3 , difficulty swallowing claim 3 , difficulty breathing claim 3 , difficulty chewing claim 3 , difficulty walking claim 3 , fasciculations claim 3 , and/or worsening posture.5. The method of claim 1 , wherein the amount of pridopidine is effective to enhance BDNF axonal transport in motor neurons claim 1 , enhance ERK activation in motor neurons claim 1 , improve NMJ formation and preservation claim 1 , preserve NMJ structure claim 1 , preserve NMJ function claim 1 , improve innervation rate of muscle tissue claim 1 , enhance motor neuron axonal growth claim 1 , reduce axonal degeneration claim 1 , reduce motor neuron axonal degeneration claim 1 , enhance muscle cell survival claim 1 , enhance muscle fiber diameter and function claim 1 , reduce SOD1 aggregation claim 1 , lessen pseudobulbar disease progression claim 1 , reduce progression of muscle fiber wasting claim 1 , and/or improve muscle contraction in the subject afflicted with ALS.6. The method of claim 1 , wherein ...

Methods of Blocking the CXCR-4/SDF-1 Signaling Pathway With Inhibitors of Bruton's Tyrosine Kinase

In some embodiments, the present invention relates to novel small molecule inhibitors that block the CXCR4-SDF-1 signaling pathway by directly inhibiting the members of the Tec family of kinases, namely Bronc's tyrosine kinese (BTK) and their use in treating disorders in which pathogenesis is mediated by the CXCR4-SDF- 1 signaling pathway.

Oral suspension of temozolomide

The present invention concerns a pharmaceutical composition, advantageously a liquid suspension, comprising: a. temozolomide or a salt thereof; b. at least one agent controlling the solid state of temozolomide in suspension; c. a pharmaceutically acceptable liquid vehicle, advantageously water; d. optionally at least one acid in a quantity so that the pH of the composition is below 5; or a powder blend for reconstituting said suspension.

Treatment of liver disease

Aspects and embodiments of the present invention relate to the treatment of fatty liver diseases such as for example, Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH). Particularly, but not exclusively certain embodiments relate to activators of glucokinase (GKAs) for use in the treatment of these fatty liver diseases. Also included in the present invention are inter alia pharmaceutical compositions comprising the GKAs, together with methods of treating such disorders as well as other subject matter.

Methods for treating cognitive deficits associated with fragile x syndrome

Provided herein are methods of treating a cognitive deficit, including cognitive deficits associated with a Fmr1 genetic defect. More particularly, provided herein are methods in which an effective amount of a MDM2-p53 pathway inhibitor is administered to a subject afflicted with at least one cognitive deficit, whereby administration of the inhibitor improves, enhances, or rescues at least one cognitive deficit in the subject.

Hydrogel-forming peptides

Provided are hydrogel-forming peptides that comprise at least one dyad of hydrophobic amino acid residues in which one is a β 3 - or β 2 -homo amino acid residue. The hydrogels derived from these peptides can be loaded with biological materials and can be used in physiological conditions.

Compounds, compositions, methods for treating diseases, and methods for preparing compounds

Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as head and neck squamous cell carcinoma (HNSCC), cancer, blood disorders, etc.). Additional embodiments provide synergistic combinations of a BCL2 inhibitor with an IRAK inhibiting compound, and methods of using same.

Engaging the cervical spinal cord circuitry to re-enable volitional control of hand function in tetraplegic subjects

In various embodiments, methods are provided for applying transcutaneous and/or epidural spinal cord stimulation with and without selective pharmaceuticals to restore voluntary control of hand function in tetraplegic subjects.

Pathogenic control of apoptosis

The present invention relates to methods and compositions for modulating the control of apoptosis, specifically for modulating the interaction between hnRNP-K and lincRNA-p21 to induce or prevent apoptosis in the cell.

Cystatin c and galectin-3 as biomarkers for pulmonary arterial hypertension

Cystatin C (CysC) and Galectin 3 (Gal-3) are biomarkers for pulmonary arterial hypertension (PAH), wherein elevated levels of one or other or both CysC and Gal-3 indicates a likelihood of PAH. Also provided are methods for identifying candidates for pulmonary arterial hypertension treatment and methods for monitoring therapeutic treatments of pulmonary arterial hypertension by monitoring levels of CysC and Gal-3 in the subject undergoing therapy.

DEUTERATED MORPHINAN COMPOUNDS FOR TREATING AGITATION

This invention relates to methods of treating agitation comprising administering a morphinan compound or a pharmaceutically acceptable salt thereof. This invention also provides the use in methods of treating agitation and related disorders with such a morphinan compound in combination with quinidine, or pharmaceutically acceptable salt of either or both thereof. 2. The method of claim 1 , wherein Ris —CHCH claim 1 , —CDCH claim 1 , —CHCD claim 1 , or —CDCD; and Ris —CHor —CD.3. The method of claim 1 , wherein for the compound of Formula I claim 1 , any atom not designated as deuterium is present at its natural isotopic abundance.5. The method of claim 3 , further comprising administering to the subject an amount of quinidine claim 3 , or a pharmaceutically acceptable salt thereof claim 3 , wherein the amount of quinidine claim 3 , or a pharmaceutically acceptable salt thereof claim 3 , is in the range of 1 mg/day to 40 mg/day.6. The method of claim 5 , wherein the amount of the compound of Formula I is in the range of 5 mg/day to 250 mg/day.7. The method of claim 1 , wherein the agitation is associated with a disorder selected from the group consisting of Alzheimer's disease claim 1 , a degenerative neurological disorder claim 1 , a mood disorder claim 1 , substance abuse withdrawal claim 1 , selective serotonin reuptake inhibitor (SSRI) withdrawal claim 1 , withdrawal from benzodiazepines claim 1 , withdrawal from drugs useful for the treatment of attention deficit disorder (ADD) and attention deficit hyperactive disorder (ADHD) claim 1 , traumatic brain injury claim 1 , terminal illness claim 1 , post-operative agitation claim 1 , post-anesthetic agitation claim 1 , Reye's syndrome and a pediatric disorder.8. The method of wherein the degenerative neurological disorder is Parkinson's disease or Huntington's disease.9. The method of wherein the mood disorder is depression claim 7 , dysthymia claim 7 , schizophrenia or bipolar disorder.10. The method of wherein the ...

Antibiotic gel formulation and methods of preparing the antibiotic gel formulation

Antibiotic gel formulations for use in dental applications are disclosed. More particularly, the present disclosure is directed to antibiotic gel formulations including low concentrations of antibiotics that are capable of killing root canal pathogens without harming the stem cells inside the root canal. Additionally, the present disclosure is directed to delivery systems and methods for applying the antibiotic gel formulations into a subject's intracanal region.

Cetirizine ophthalmic compositions

The present invention relates to an ophthalmic composition comprising cetirizine and one or more pharmaceutically acceptable excipients, wherein said composition is free of benzalkonium chloride and/or dibasic sodium phosphate. The invention particularly relates to a 0.24% cetirizine ophthalmic composition, wherein said composition is free of benzalkonium chloride and/or dibasic sodium phosphate. Further, the invention may also provide a process of preparing such composition and their use for treating allergic conjunctivitis and/or allergic rhinoconjunctivitis.

Methods and compositions for treating conditions associated with spinal cord injury

In one aspect, a method of treating a condition associated with spinal cord injury is disclosed, wherein an agent that inhibits excitatory neurons and/or activates inhibitory interneurons may be administered to an individual in need thereof. Articles of manufacture and kits related to the disclosed methods are also disclosed.

TREATMENT OF NEURODEGENERATIVE DISEASES

Methods for the prevention and treatment of neurodegenerative diseases, in particular motor neuron diseases such as amyotrophic lateral sclerosis (ALS), is described, as well as compositions and combined preparations for use in the methods. The methods comprise inhibiting EGFR signalling, and inhibiting MyD88-dependent TLR/IL-R1 signalling, in the central nervous system of a subject in need of such prevention or treatment. The compositions comprise an inhibitor of EGFR signalling, and an inhibitor of MyD88-dependent TLR/IL-R1 signalling. 1. A method of preventing or treating a neurodegenerative disease , which comprises inhibiting EGFR signalling , and inhibiting MyD88-dependent TLR/IL-R1 signalling , in the central nervous system of a subject in need of such prevention or treatment.2. A method according to claim 1 , wherein EGFR signalling and MyD88-dependent TLR/IL-R1 signalling are inhibited in microglial cells claim 1 , astrocytes claim 1 , or neurons of the subject.3. A method according to or claim 1 , wherein EGFR signalling is inhibited so as to inhibit microglial cell activation and/or formation of inclusions of TDP43.4. A method according to claim 3 , wherein formation of inclusions of TDP43 is inhibited by inducing deacetylation of TDP43.5. A method according to any preceding claim claim 3 , wherein EGFR signalling is inhibited by inhibiting EGFR tyrosine kinase activity in the subject.6. A method according to any preceding claim claim 3 , wherein EGFR signalling is inhibited by administering an inhibitor of EGFR tyrosine kinase to the subject.7. A method according to claim 6 , wherein the tyrosine kinase inhibitor is a small molecule tyrosine kinase inhibitor selected from the group consisting of gefitinib claim 6 , erlotinib claim 6 , brigatinib claim 6 , lapatinib claim 6 , afatinib claim 6 , and icotinib.8. A method according to or claim 6 , wherein the EGFR tyrosine kinase inhibitor is co-administered claim 6 , or administered sequentially to the ...

PHARMACEUTICAL COMPOSITIONS COMPRISING DEXTROMETHORPHAN AND QUINIDINE FOR THE TREATMENT OF AGITATION IN DEMENTIA

This disclosure provides pharmaceutical compositions comprising dextromethorphan in combination with quinidine, and methods for treating agitation and/or aggression in subjects with dementia by administering such compositions. 1. A method of treating agitation and/or aggression and/or associated symptoms in a subject with dementia comprising administering to a subject in need thereof dextromethorphan , or a pharmaceutically acceptable salt thereof , in combination with quinidine , or a pharmaceutically acceptable salt thereof.2. The method of claim 1 , wherein dextromethorphan is administered in an amount ranging from about 10 mg to about 200 mg per day claim 1 , and wherein quinidine is administered in an amount ranging from about 0.05 mg to less than about 50 mg per day.3. The method according to claim 1 , wherein the dementia is of the Alzheimer's type.4. The method according to claim 1 , wherein quinidine is administered in an amount ranging from about 4.75 mg to about 20 mg per day.5. The method according to claim 1 , wherein dextromethorphan is administered in an amount ranging from about 15 mg to about 90 mg per day.6. The method according to claim 1 , wherein at least one of the quinidine and the dextromethorphan is in the form of a pharmaceutically acceptable salt chosen from salts of alkalai metals claim 1 , salts of lithium claim 1 , salts of sodium claim 1 , salts of potassium claim 1 , salts of alkaline earth metals claim 1 , salts of calcium claim 1 , salts of magnesium claim 1 , salts of lysine claim 1 , salts of N claim 1 ,N′dibenzylethylenediamine claim 1 , salts of chloroprocaine claim 1 , salts of choline claim 1 , salts of diethanolamine claim 1 , salts of ethylenediamine claim 1 , salts of meglumine claim 1 , salts of procaine claim 1 , salts of tris claim 1 , salts of free acids claim 1 , salts of free bases claim 1 , inorganic salts claim 1 , salts of sulfate claim 1 , salts of hydrochloride claim 1 , and salts of hydrobromide.7. The method ...

Software integration object linking data structures

Techniques and solutions are described for providing integration objects that can be used to enhance data retrieval, and can be used to provide shared data access for multiple applications, and to allow access to application functionality through an interface. The integration object includes a plurality of integration data objects, at least a portion of which are mapped to data objects stored in one or more data sources. The integration data objects can hold values stored in correspondingly mapped locations of the data objects, such as in a value field. A reference field of the integration data objects can hold reference information regarding a location of a value in a respectively mapped data source. At least a portion of the integration data objects can include a defined sequencing with one or more other integration data objects.

New process for the synthesis of piperazinyl-ethoxy-bromophenyl derivates and their application in the production of compounds containing them

Process for the industrial synthesis of the compound of formula (I):

Vilazodone inclusion complexes, compositions and preparation thereof

Disclosed herein are inclusion complexes comprising vilazodone or a pharmaceutically acceptable salt thereof and an inclusion material, compositions and pharmaceutical formulations comprising the inclusion complexes, and methods for preparing the inclusion complexes, compositions or pharmaceutical formulations.

Methods and compositions involving rad51 inhibitors

The present invention concerns methods and compositions involving inhibitors and of RAD51, a protein involved in homologous recombination. In some embodiments, there are methods for sensitizing cells to the effects of DNA damaging agents, which can have particular applications for cancer patients. In some embodiments of the invention, the RAD51 inhibitor is a small molecule that directly affects RAD51 activity, such as its ability to promote filament formation.

Taste-masked pharmaceutical compositions with gastrosoluble pore-formers

There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredient(s), rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates on contact with saliva in the buccal cavity forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing the active), coated with a taste-masking membrane comprising a water-insoluble polymer and one or more gastrosoluble inorganic or organic pore-formers (practically insoluble in water and saliva, but soluble in an acidic buffer), exhibit acceptable taste-masking when placed in the oral cavity and provide rapid, substantially-complete release of the dose on entry into the stomach.

Pharmaceutical compositions for treating diabetes and preparation method thereof

An oral dosage form of a pharmaceutical composition for managing diabetes in a subject is provided, which comprises a core, a controlled membrane film, and an outer film. The core comprises a first antidiabetic agent. The controlled membrane film coats the core tablet and can realize a controlled release of the first antidiabetic agent from the core into a portion of a digestive tract of the subject corresponding to a stomach and an upper gastrointestinal tract after the pharmaceutical composition is orally administered to the subject. The controlled membrane film comprises at least one controlling polymer, each selected from an Eudragit polymer, an Aquacoat polymer, or an Ethocel polymer. The outer film comprises a second antidiabetic agent, and coats the controlled membrane film. A method for manufacturing an oral dosage form of a pharmaceutical composition is also provided.

Pharmaceutical Compositions Comprising Levocetirizine

Disclosed are pharmaceutical compositions comprising levocetirizine.

Methods of Treating Eye Disorders

The present invention is related to a method of treating a patient having an eye disorder selected from the group consisting of presbyopia, glaucoma, or halos and glare, the method comprising administering to the patient a liquid composition comprising a pharmacologically effective amount of dapiprazole or its pharmaceutically acceptable salt.

Covalent inhibitors of cdk-7

The disclosure includes compounds of Formula (I) wherein R 0 , R 1 , R 2 , R 3 , R 4 , R 5 , and L are defined herein. Also disclosed is a method for treating a neoplastic disease, autoimmune disease, and inflammatory disorder with these compounds.

A cftr corrector for the treatment of genetic disorders affecting striated muscle

The present invention relates to the use of CFTR correctors in the treatment of genetic disorders affecting striated muscle selected from sarcoglycanopathies, Brody's disease (BD) and the recessive forms of Cathecolaminergic Polymorphic Ventricular Tachycardia (CPVT).

Methods and compositions of anti-inflammatory drug and dicer activator for treatment of neuronal diseases

The present invention discloses compositions, means and kits thereof for treating neuronal clinical indications in a mammalian subject. The composition comprises, inter alia, a synergistic combination of an anti-inflammatory drug and a DICER activator. The present invention further discloses methods for treating neuronal diseases including Motor neuron diseases (MNDs), ALS, FTD (Frontotemporal Dementia), macular degeneration (AMD) autism, and neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease.